drugset / Trial / NCT04175171
Clinical Trial of Comparative Study of GB221 Pharmacokinetics
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.
Timeline
- Start
- 2011-11-07
- Primary completion
- 2012-01-08
- Completion
- 2012-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coprelotamab | Unknown | 8 mg/kg | Intravenous |
| Comparator | Trastuzumab | Monoclonal antibody | 8 mg/kg | Intravenous |